^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Lung Adenocarcinoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    Chugai’s Tecentriq Obtains Regulatory Approval as the First Immunotherapy in Japan for Adjuvant Treatment of Non-small Cell Lung Cancer

    Excerpt:
    Chugai Pharmaceutical...announced that it obtained regulatory approval for an additional indication of the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody Tecentriq® Intravenous Infusion 1200 mg [generic name: atezolizumab (genetical recombination)] for the adjuvant treatment of PD-L1-positive non-small cell lung cancer (NSCLC) from the Ministry of Health, Labour and Welfare....VENTANA OptiView PD-L1 (SP263), a pathological testing kit marketed by Roche Diagnostics K.K., should be used to detect PD-L1 expression.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC). studio in aperto seguito da una fase randomizzata in doppio cieco a gruppi paralleli con studio di estansione, per indagare la sicurezza e l'efficacia di GB1211 in cominazione con Atezolizumab in pazienti affetti da carcinoma polmonare non a piccole cellule

    Excerpt:
    ...Expressing PD-L1 on at least 50% of tumour cells. ...
    Trial ID:
    2021-003189-11
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Gan To Kagaku Ryoho
    Title:

    [Effectiveness of Atezolizumab Combination Therapy for PD-L1(SP142)Positive Lung and Breast Double Cancer-A Case Report]

    Excerpt:
    We report a case in which atezolizumab was efficiency in PD-L1 (SP142)-positive lung and breast double cancer...Pretreatment diagnosis was lung adenocarcinoma, cT2a, N2/3, M1b/1c(HEP, OSS), Stage III A/B or IV A/B(PD-L1 positive), and right breast cancer, T4b, N2, M0/1 (HEP, OSS, LYM), Stage III B or IV triple-negative(PD-L1 positive)double cancer. We underwent surgery(mastectomy with axillar lymph nodes dissection), followed by immunochemotherapy(atezolizumab, carboplatin, paclitaxel)and it was efficiency.
    Secondary therapy:
    carboplatin + bisphosphonate bound paclitaxel
    Test:
    VENTANA PD-L1 (SP142) Assay